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Abstract
Background: Atrial fi brillation (AF) and chronic kidney disease (CKD) have both been 
shown to portend worse outcomes after acute myocardial infarction (MI); however, the benefi t 
of a rhythm control strategy in patients with CKD post-MI is unclear.
Methods: We prospectively studied 985 patients with new-onset AF post-MI in the 
GUSTO-III trial, of whom 413 (42%) had CKD (creatinine clearance < 60 mL/min). 
A rhythm control strategy, defi ned as the use of an antiarrhythmic medication and/or 
electrical cardioversion, was used in 346 (35%) of patients.
Results: A rhythm control strategy was used in 34% of patients with CKD and 36% of patients 
with no CKD. At hospital discharge, sinus rhythm was present in 487 (76%) of patients treated 
with a rate control strategy, vs. 276 (80%) in those treated with rhythm control (p = 0.20). CKD 
was associated with a lower odds of sinus rhythm at discharge (unadjusted OR 0.56, 95% CI 
0.38–0.84, p < 0.001). However, in multivariable analyses, treatment with a rhythm control 
strategy was not associated with discharge rhythm (HR 1.068, 95% CI 0.69–1.66, p = 0.77),
 30-day mortality (HR 0.78, 95% CI 0.54–1.12, p = 0.18) or mortality from day 30 to 1 year 
(HR 1.00, 95% CI 0.59–1.69, p = 0.99). CKD status did not signifi cantly impact the relation-
ship between rhythm control and outcomes. 
Conclusions: Treatment with a rhythm or rate control strategy does not signifi cantly impact 
short-term or long-term mortality in patients with post-MI AF, regardless of kidney disease sta-
tus. Future studies to investigate the optimal management of AF in CKD patients are needed. 
(Cardiol J 2013; 20, 4: 439–446)
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Introduction
Atrial fi brillation (AF) is twice as prevalent 
among patients with chronic kidney disease (CKD) 
and over 10 times more prevalent in patients on 
dialysis than in the general population [1, 2]. In 
the Chronic Renal Insuffi ciency Cohort of 3,267 
adult participants, nearly 1 in 5 participants had 
evidence of AF; age, female gender, and a history 
of cardiovascular disease were the major predictors 
of AF in the study. Also, among 956 outpatients 
with coronary artery disease in the Heart and 
Soul Study, kidney dysfunction was independently 
associated with prevalent AF [3]. Although each of 
these groups of patients is at high risk for cardio-
vascular mortality and morbidity, little is known 
about the impact of AF treatment strategy on 
clinical outcomes in patients with kidney disease. 
As such, the optimal management of AF in this 
population is unknown. 
AF in the setting of acute myocardial in-
farction (MI) is associated with worse outcomes 
[4]. Although antiarrhythmic medications with or 
without electrical cardioversion may restore sinus 
rhythm (SR) in these patients, their ability to im-
prove post-MI survival is unclear. In the Valsartan 
in Acute Myocardial Infarction (VALIANT) Trial, 
antiarrhythmic use was associated with excess 
short-term mortality in the peri-MI period but not 
long-term mortality [5]. Results from the Global 
Use of Strategies to Open Occluded Coronary 
Arteries III (GUSTO-III) AF substudy suggested 
a trend toward lower mortality with the use of 
sotalol and procainamide in post-MI patients with 
AF [6]. The effect of CKD on these outcomes is 
unknown. This is an issue of particular clinical 
signifi cance, because CKD itself is a risk factor for 
increased mortality after acute MI [7, 8].
Using prospective data from the GUSTO-III 
trial, we conducted an analysis to investigate the 
use of a rhythm control strategy in patients with 
CKD and post-MI AF and to study its impact on the 
maintenance of SR, 30-day and 1-year mortality.
Methods
Study population
The GUSTO-III trial was an international study 
of over 15,000 patients treated for acute MI with 
ST-segment elevation or new left bundle-branch 
block and randomized to alteplase or reteplase 
therapy between October 13, 1995 and January 13, 
1997 [9]. A cohort of 1,138 subjects who developed 
AF during the study period was enrolled into a pro-
spective substudy of post-MI AF management [6]. 
Patients were treated either with a rate control only 
strategy using atrioventricular nodal blocking agents 
or a rhythm control strategy using antiarrhythmic 
medications and/or electrical cardioversion. Treat-
ment decisions were made by the primary medical 
team and were not randomized, but this pre-speci-
fi ed observational analysis investigated outcomes 
including the maintenance of SR, and mortality at 
30 days and 1 year post-MI. Patients were excluded 
from this analysis if they had longstanding persistent 
or permanent AF at study entry.
The details of patient enrollment and data 
collection have been previously described [9]. 
The Duke University Medical Center Institutional 
Review Board approved the study protocol, and all 
patients provided informed written consent for the 
collection of clinical data and blood samples before 
participation in the GUSTO-III trial. 
Data collection
This was a prospective cohort analysis of 
outcomes in the GUSTO-III AF substudy, stra-
tified by the presence or absence of CKD (defi-
ned as a calculated creatinine clearance below 
60 mL/min/1.73 m2) at the time of enrollment. The 
primary outcome measure was 1-year survival post 
AF onset. Secondary outcomes included 30-day 
survival post AF onset and the presence of SR at the 
time of hospital discharge or last stable rhythm prior 
to death. The goal of the proposed analysis was to in-
vestigate the use of a rate vs. rhythm control strategy 
in patients with post-MI AF and to study the impact 
of CKD and treatment strategy on the maintenance 
of SR, 30-day and 1-year mortality. Data collected as 
part of the substudy included the use of ventricular 
rate controlling agents (beta-blockers, calcium anta-
gonists, or digitalis), the use of any antiarrhythmic 
agent (procainamide, quinidine, disopyramide, encai-
nide, fl ecainide, propafenone, sotalol and amiodarone) 
or electrical cardioversion for rhythm control, the 
use of antiplatelet and anticoagulant medications at 
hospital discharge, and the cardiac rhythm at hospital 
discharge or the last stable rhythm recorded before 
deterioration to in-hospital death. 
Statistical analysis
Baseline variables were compared between 
groups using the Wilcoxon rank-sum test for con-
tinuous variables and the Pearson c2 or Exact test 
for categorical variables. The product-limit method 
was used to model the event-free survival of sub-
jects, and survival curves were compared using 
the log-rank test. Factors associated with survival 
time after the onset of AF were assessed in uni-
variate and multivariable Cox proportional hazards 
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models. In addition to CKD and treatment strategy, 
covariates previously known to be associated with 
mortality in the GUSTO trial were included in the 
models [9, 10]. Additionally, factors associated 
with maintenance of SR at hospital discharge were 
modeled using multivariable logistic regression. 
Candidate variables selected by the study investi-
gators were considered in multivariable stepwise 
regression models, and a 2-tailed p value of < 0.05 
was considered statistically signifi cant. Analyses 
were performed using SAS, version 9.2, software 
(SAS Institute, Cary, NC).
Results
Population characteristics
Of the 1,138 patients enrolled in the GUSTO-III 
AF substudy, 153 were excluded due to a history 
of longstanding persistent or permanent AF. Thus, 
985 patients met our inclusion criteria and were 
represented in this analysis. Of these patients, 
639 (65%) were treated with a rate control only 
strategy, and 346 (35%) were treated with a rhythm 
control strategy during the index hospitalization. 
The baseline characteristics of the cohort are 
shown in Table 1. Subjects who received rhythm 
control on average had higher heart rates at en-
rollment and were more likely to present with an 
anterior MI than those who received a rate control 
strategy; otherwise, no signifi cant differences in 
demographic characteristics or baseline medical 
conditions were noted between the two groups. 
Additionally, there was no signifi cant difference in 
the percentage of patients managed with a rhythm 
control strategy in the CKD vs. non-CKD groups 
(34% vs. 36%). Subjects with CKD had a mean 
Table 1. Baseline characteristics of the cohort by treatment strategy and by chronic kidney disease 
(CKD) status.
Rate vs. rhythm control CKD vs. non-CKD
Rate 
(n = 639)
Rhythm 
(n = 346)
P CKD 
(n = 413)
Non-CKD 
(n = 559)
P
Age [years]* 69.9 ± 10.5 68.4 ± 10.9 0.054 75.9 ± 7.6 64.6 ± 9.9 < 0.001
White race 95.4% 96.0% 0.752 97.3% 94.6% 0.022
Women 34.1% 34.1% 0.997 50.6% 21.6% < 0.001
Hypertension 49.0% 46.5% 0.462 51.1% 46.5% 0.158
Hyperlipidemia 30.4% 35.5% 0.108 27.0% 35.9% 0.003
Prior coronary bypass 3.1% 3.2% 0.966 2.7% 3.6% 0.423
Prior coronary 
angioplasty/stent
5.3% 4.9% 0.783 4.4% 5.7% 0.341
Prior MI 22.7% 20.5% 0.432 24.5% 20.0% 0.100
Tobacco history 64.7% 64.5% 0.400 55.7% 71.2% < 0.001
Cerebrovascular disease 3.1% 2.9% 0.831 4.1% 2.3% 0.109
Systolic blood pressure 118.1 ± 27.5 117.0 ± 24.4 0.486 118.0 ± 27.1 117.9 ± 25.6 0.890
Diastolic blood pressure 72.1 ± 36.6 69.6 ± 15.0 0.376 70.9 ± 35.8 71.7 ± 26.2 0.427
Heart rate 107.4 ± 35.5 122.6 ± 33.1 < 0.001 111.7 ± 34.6 114.0 ± 35.9 0.289
Killip class: 0.048 < 0.001
I 75.8% 75.7% 68.8% 80.9%
II 20.7% 20.6% 26.8% 16.2%
III 1.3% 3.2% 2.2% 1.8%
IV 2.2% 0.6% 2.2% 1.1%
MI location: 0.009 0.425
Anterior 43.8% 54.6% 49.4% 46.3%
Inferior 51.6% 41.6% 45.8% 50.1%
Other 4.2% 3.5% 4.6% 3.2%
LVEF [%]* 45.7 ± 14.3 45.6 ± 14.2 0.677 45.1 ± 16.4 45.9 ± 13.0 0.691
Creatinine [mg/dL]* 1.02 ± 0.30 1.01 ± 0.30 0.376 1.17 ± 0.35 0.91 ± 0.21 < 0.001
Creatinine clearance 
[mL/min]*
67.6 ± 28.1 70.8 ± 30.2 0.154 44.9 ± 10.6 86.3 ± 25.3 < 0.001
*Continuous variables given as mean ± SD; MI — myocardial infarction; LVEF — left ventricular ejection fraction
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creatinine clearance of 45 mL/min, were older, 
more likely to be white and female, tended to have 
slightly worse Killip class, and were less likely to 
have a history of hyperlipidemia and smoking than 
subjects without CKD. 
Management strategy
Table 2 summarizes the details of the treat-
ment strategy in the rhythm control group. In this 
group, 30% (103) received electrical cardioversion, 
55% of whom had a primary cardioversion strategy, 
as opposed to antiarrhythmic medication use fol-
lowed by cardioversion. Amiodarone and procai-
namide were the principal antiarrhythmic agents 
used in the rhythm control cohort, used in 70% of 
subjects. Procainamide was used less frequent-
ly in CKD patients than in non-CKD patients 
(p = 0.025); no difference was seen with the 
use of other antiarrhythmic agents. Class IC an-
tiarrhythmics were used infrequently in the cohort. 
Specifi cally, fl ecainide was only used in 2 subjects, 
and encainide was not used at all, very likely due to 
their known association with increased mortality 
in the post-MI setting.
Table 3 shows the use of antiplatelet and 
anticoagulant medications at hospital discharge, 
in each subgroup. Notably, patients in the rhythm 
control group were more likely to receive warfarin 
at discharge than those in the rate control group; 
the rates of use of other antithrombotics in the 
two groups were similar. In addition, patients with 
CKD were less likely to receive aspirin and other 
antiplatelet medication than those without CKD; 
warfarin and subcutaneous heparin, however, were 
used similarly in CKD and non-CKD patients.
Survival analysis
At follow-up, there were a total of 154 (15.6%) 
deaths within 30 days and 222 (22.5%) deaths at 
1 year. Kaplan-Meier curves for survival from the 
time of AF onset up to 1 year are displayed in 
the Figure 1. Observed survival differences were 
largest between those with and without CKD 
(log-rank p-value < 0.001), with non-signifi cant 
differences between rate and rhythm control 
strategies (log-rank p-value = 0.109). Table 4 
shows that in univariate analysis, there was 
a statistically signifi cant association between CKD 
and increased mortality at 30 days (unadjusted 
HR 2.4, 95% CI 1.7–3.3, p < 0.001) and from day 
30 to 1 year (unadjusted HR 1.7, 95% CI 1.1–2.8, 
p = 0.027). However, in multivariable analyses, the 
Table 3. Antithrombotic use in the cohort at hospital discharge.
Rate vs. rhythm control CKD vs. non-CKD
 
Rate 
(n = 639)
Rhythm 
(n = 346)
P CKD 
(n = 413)
Non-CKD 
(n = 559)
P
Aspirin 76.4% 76.5% 0.982 71.5% 79.5% 0.006
Warfarin 16.0% 22.8% 0.008 19.4% 17.7% 0.509
Heparin (subcutaneous) 1.4% 2.3% 0.299 1.0% 2.3% 0.111
Other antiplatelet (thienopyridine, 
dipyridamole)
11.1% 9.0% 0.290 7.0% 12.7% 0.004
CKD — chronic kidney disease
Table 2. Summary of antiarrhythmic management in the rhythm control group.
Total* (n = 346) CKD** (n = 142) Non-CKD** (n = 201) P
Amiodarone 45.4% (157) 50.0% (71) 41.8% (84) 0.362
Procainamide 24.6% (85) 18.3% (26) 28.9% (58) 0.025
Sotalol 11.8% (41) 12.0% (17) 11.9% (24) 0.892
Propafenone 5.8% (20) 5.6% (8) 6.0% (12) 0.820
Quinidine 5.2% (18) 5.6% (8) 5.0% (10) 0.866
Disopyramide 0.9% (3) 1.4% (2) 0.5% (1) 0.578
Flecainide 0.6% (2) 0.7% (1) 0.5% (1) 1.000
*Some subjects in rhythm control group received electrical cardioversion without antiarrhythmic medications; **creatinine clearance data 
missing in 3 subjects; CKD — chronic kidney disease
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association between CKD and mortality became 
non-signifi cant. In addition, regardless of kidney 
disease status, treatment with a rate vs. rhythm 
control strategy was not signifi cantly associated 
with mortality (p value for interaction between 
CKD and treatment strategy = 0.89 for 30-day and 
0.38 for 1-year mortality).
Effi cacy of rhythm control
Sinus rhythm was present at hospital dischar-
ge in 487 (76%) of patients treated with a rate 
control strategy, vs. 276 (80%) in those treated with 
rhythm control (p = 0.20). In univariate analysis, 
CKD was associated with a lower odds of SR at 
discharge (unadjusted OR 0.56, 95% CI 0.38–0.84, 
p < 0.001), as shown in Table 5. In multivariable 
analysis that adjusted for potential confounders, 
however, treatment with a rhythm control stra-
tegy was not associated with discharge rhythm 
(HR 1.068, 95% CI 0.69–1.66, p = 0.77), 30-day 
mortality (HR 0.78, 95% CI 0.54–1.12, p = 0.18) 
or mortality from day 30 to 1 year (HR 1.00, 95% CI 
Figure 1. Unadjusted survival curves for all-cause mortality up to 1 year; CKD — chronic kidney disease.
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Table 4. Proportional hazards models for all-cause mortality.
Analysis Atrial fibrillation onset to Day 30* Day 30 to 1 year**
Hazard 
ratio
95% confidence 
interval
P Hazard 
ratio
95% confidence 
interval
P
Univariate:
Kidney disease 2.40 1.73–3.34 < 0.001 1.72 1.07–2.76 0.027
Strategy (rhythm vs. rate) 0.73 0.52–1.04 0.073 0.94 0.57–1.55 0.809
Multivariable:
Kidney disease 1.42 0.92–2.20 0.118 0.90 0.49–1.65 0.735
Strategy (rhythm vs. rate) 0.78 0.54–1.12 0.183 1.00 0.59–1.69 0.992
*Multivariable model adjusted for age, weight, entry blood pressure, Killip class at entry, smoking status, prior coronary artery bypass 
grafting, hypertension, cerebrovascular disease, diabetes mellitus, entry pulse, previous myocardial infarction and time from symptom 
onset to atrial fibrillation. Interaction between kidney disease and strategy was found not statistically significant (p = 0.8899) 
**Multivariable model adjusted for age, weight, entry blood pressure, Killip class at entry, smoking status, prior coronary artery bypass 
grafting, hypertension, cerebrovascular disease, diabetes mellitus, entry pulse, previous myocardial infarction, prior percutaneous translu-
minal coronary angioplasty, previous angina, myocardial infarction location, race, gender and US enrollment. Interaction between kidney 
disease and strategy was found not statistically significant (p = 0.3815)
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0.59–1.69, p = 0.99) (Tables 4, 5). Additionally, the 
lack of association between treatment strategy and 
discharge rhythm was not signifi cantly different in 
CKD patients (p value for interaction between CKD 
and treatment strategy = 0.30).
Sensitivity analysis
Regression analyses were repeated to examine 
the effect of moderate to severe CKD, defi ned as 
a creatinine clearance < 45 mL/min, on clinical 
outcomes (Tables 6, 7). In multivariable analysis, 
there was an almost 2-fold increase in mortali-
ty associated with moderate to severe CKD at 
30 days (HR 1.93, 95% CI 1.28–2.92, p = 0.002) and 
from day 30 to 1 year (HR 1.93, 95% CI 1.02–3.66, 
p = 0.04). There was no signifi cant association 
between treatment with a rate vs. rhythm control 
strategy and mortality in the subgroup with creati-
nine clearance < 45 mL/min (p value for interaction 
between moderate to severe CKD and treatment 
strategy = 0.40 both for 30-day and for 1-year 
mortality). There was a difference, however, in the 
effect of treatment strategy on discharge rhythm 
in this subgroup. While in the overall cohort there 
was no association between treatment strategy and 
discharge rhythm, in the patients with moderate to 
severe CKD, there was a lower probability of SR 
at discharge with a rhythm control strategy (ad-
justed OR 0.43, 95% CI 0.19–0.99, p value for 
interaction between moderate to severe CKD and 
treatment strategy = 0.01). 
Discussion
In this prospective cohort analysis of patients 
with AF complicating acute MI, we examined the 
Table 5. Odds ratios for sinus rhythm at discharge.
Analysis Odds ratio 95% confidence interval P
Univariate:
Kidney disease 0.56 0.375–0.838 < 0.001
Strategy (rhythm vs. rate) 1.18 0.772–1.792 0.447
Multivariable*:
Kidney disease 0.829 0.506–1.357 0.4553
Strategy (rhythm vs. rate) 1.068 0.687–1.661 0.7706
*Multivariable analysis adjusted for age, diastolic blood pressure (pressure > 85), Killip class at entry. Interaction term between kidney 
disease and strategy was found not statistically significant (p = 0.3023)
Table 6. Sensitivity analysis for all-cause mortality in moderate to severe chronic kidney disease.
Atrial fibrillation onset to Day 30* Day 30 to 1 year**
Hazard 
ratio
95% confidence 
interval
P Hazard 
ratio
95% confidence 
interval
P
Multivariable analysis
Creatinine clearance < 45 1.93 1.28–2.92 0.002 1.93 1.02–3.66 0.045
Strategy (rhythm vs. rate) 0.76 0.53–1.09 0.136 0.96 0.57–1.63 0.890
*Model adjusted for age, weight, entry blood pressure, Killip class at entry, smoking status, prior coronary artery bypass grafting, hyper-
tension, cerebrovascular disease, diabetes mellitus, entry pulse, previous myocardial infarction and time from symptom onset to atrial 
fibrillation. Interaction between moderate to severe chronic kidney disease and strategy was found not statistically significant (p = 0.3974) 
**Model adjusted for age, weight, entry blood pressure, Killip class at entry, smoking status, prior coronary artery bypass grafting, hyper-
tension, cerebrovascular disease, diabetes mellitus, entry pulse, previous myocardial infarction, prior percutaneous transluminal coronary 
angioplasty, previous angina, myocardial infarction location, race, gender and US enrollment. Interaction between moderate to severe 
chronic kidney disease and strategy was found not statistically significant (p = 0.3979)
Table 7. Sensitivity analysis for sinus rhythm at hospital discharge in moderate to severe chronic 
kidney disease.
Multivariable analysis* Odds ratio 95% confidence interval P
Creatinine clearance < 45 0.90 0.53–1.55 0.711
Strategy (rhythm vs. rate) 1.06 0.68–1.65 0.792
*Model adjusted for age, diastolic blood pressure (pressure > 85), Killip class at entry. Interaction between moderate to severe chronic 
kidney disease and strategy was found statistically significant (p = 0.0145)
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impact of both CKD and treatment with a primary 
rate or rhythm control strategy on clinical outco-
mes. Over a third of subjects in the GUSTO-III 
substudy who developed AF were treated with 
a rhythm control strategy, which primarily consisted 
of antiarrhythmic agents such as amiodarone or 
procainamide. Thirty percent of patients recei-
ved electrical cardioversion, either alone or with 
adjunctive antiarrhythmic therapy. There was no 
signifi cant difference in the use of rhythm control 
between the CKD and non-CKD arms. In our study, 
treatment with a rate or rhythm control strategy 
was not signifi cantly associated with 30-day and 
1-year outcomes in multivariable analyses. In 
unadjusted analyses, subjects with CKD had incre-
ased mortality and were less likely to maintain 
SR at discharge; in multivariable analysis there 
was no signifi cant association between CKD and 
either outcome, regardless of treatment strategy. 
A sensitivity analysis was performed to investigate 
the outcomes of subjects with moderate to severe 
CKD, defi ned as creatinine clearance < 45 mL/min, 
which found a lower likelihood of maintaining SR 
at discharge with a rhythm control strategy in 
multivariable analysis.
While AF diagnosed in the setting of acute 
MI has been associated with adverse outcomes [4, 
10–13], the optimal treatment strategy of AF in this 
setting is unclear, with some studies suggesting an 
increased harm with antiarrhythmic therapy [5], 
and others either neutral or suggesting a possible 
benefi t [6, 14]. It is known that the development 
of post-MI AF is associated with other factors 
that independently portend a more complicated 
clinical course, such as older age, left ventricular 
dysfunction, and worsening heart failure [4, 15]. 
To the extent that AF is a marker of these adverse 
prognostic factors, treatment directed at control-
ling AF per se, may not necessarily improve clinical 
outcomes. In addition, the risk of pro-arrhythmia 
related to antiarrhythmic medication use has to be 
weighed against any potential benefi t of restoring 
and maintaining SR. In the present study, there was 
no signifi cant association between AF treatment 
strategy and either short- or long-term mortality. 
This suggests that, while an aggressive strategy of 
rhythm control may not be indicated in the routine 
management of all patients with post-MI AF, it is 
certainly reasonable to consider in the short-term 
management of select patients in the post-MI set-
ting, especially in patients who are symptomatic 
despite adequate rate control [6].
CKD is both a risk factor for AF [2, 16, 17] and 
an independent predictor of adverse outcomes after 
acute MI [8, 18–20]. The risks of antiarrhythmic 
therapy may be magnifi ed in patients with CKD, 
owing to the need for renal dose adjustment of 
certain antiarrhythmic agents [21], as well as to 
the co-morbidity that often accompanies CKD 
and that may promote pro-arrhythmia. The deve-
lopment of fi brosis and left ventricular hypertrophy 
associated with kidney disease is hypothesized to 
predispose CKD patients to cardiac arrhythmia and 
sudden death by its effects on the QT interval and 
QT dispersion [22, 23]. As a result, evidence from 
clinical trials on rate and rhythm control strategies 
in AF may not be generalizable to patients with 
impaired renal function, so data are limited in this 
regard. This is the fi rst study we are aware of that 
addresses the safety and effi cacy of rate vs. rhythm 
control of AF in CKD patients. Notably, despite 
high post-MI mortality rates in this cohort (15.6% 
at 30 days and 22.5% at 1 year), there was no sug-
gestion that CKD patients were at higher risk of 
short- or long-term mortality when treated with 
either a primary rate or rhythm control strategy. 
Interestingly, regardless of CKD status, there was 
no signifi cant overall impact of a rhythm control 
strategy on discharge rhythm in this population. 
This fi nding does not rule out a possible benefi t 
of rhythm control in reducing the overall duration 
and burden of AF during the hospitalization or 
improving quality of life and/or functional status, 
although this was not specifi cally addressed in our 
analysis. Results of the subgroup with moderate 
to severe CKD suggested that a rhythm control 
strategy was associated with a lower probability of 
maintaining SR at discharge. While results of any 
subgroup should be interpreted with caution, this 
is an intriguing fi nding that should be the subject 
of future prospective studies on antiarrhythmic 
management in CKD patients.
Limitations of the study
As with any observational study, the present 
one is not without some limitations. First, although 
this was a pre-specifi ed prospective analysis of 
AF management and outcomes, treatment with 
rate vs. rhythm control was not randomized and 
the potential for confounding exists. This is miti-
gated somewhat by the multivariable regression 
modeling to adjust for known confounders in the 
cohort. Second, while in-hospital management was 
recorded and accounted for in the analysis, the 
impact of interventions after hospital discharge on 
1-year mortality, such as additional medications, or 
cross-over from rate control to a rhythm control 
strategy, was not known. Also, creatinine clearance 
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was calculated using serum creatinine measure-
ments at the time of study enrollment but this 
may not accurately refl ect steady-state renal fun-
ction. Finally, amiodarone and procainamide were 
the principal antiarrhythmic medications used in 
GUSTO-III and thus results in this cohort may not 
be generalizable to contemporary practice, where 
agents such as dofetilide, sotalol, and dronedarone 
are now commonly used in the post-MI setting.
Conclusions
In patients with post-MI AF, treatment with 
a rhythm or rate control strategy does not signifi -
cantly impact short-term or long-term mortality, 
regardless of kidney disease status. Future rando-
mized trials to investigate the optimal management 
of post-MI AF in patients with CKD are needed.
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